PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Peg, Vicente
• dc.contributor.author López-García, María Ángeles
• dc.contributor.author Comerma Blesa, Laura, 1983-
• dc.contributor.author Peiró, Gloria
• dc.contributor.author García-Caballero, Tomás
• dc.contributor.author Concha López, Ángel
• dc.contributor.author Suárez-Gauthier, Ana
• dc.contributor.author Ruiz, Irune
• dc.contributor.author Rojo, Federico
• dc.date.accessioned 2021-07-13T06:32:35Z
• dc.date.available 2021-07-13T06:32:35Z
• dc.date.issued 2021
• dc.description.abstract Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.
• dc.format.mimetype application/pdf
• dc.identifier.citation Peg V, López-García MÁ, Comerma L, Peiró G, García-Caballero T, López ÁC, et al. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion. Future Oncol. 2021 Apr; 17(10): 1209-18. DOI: 10.2217/fon-2020-1100
• dc.identifier.doi http://dx.doi.org/10.2217/fon-2020-1100
• dc.identifier.issn 1479-6694
• dc.identifier.uri http://hdl.handle.net/10230/48161
• dc.language.iso eng
• dc.publisher Future Medicine
• dc.rights This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword PD-L1
• dc.subject.keyword Antibody
• dc.subject.keyword Breast cancer
• dc.subject.keyword Diagnosis
• dc.subject.keyword Immunohistochemistry
• dc.subject.keyword Immunotherapy
• dc.title PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion